24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Medical Disorders
Resources
Basic InformationLookupsLatest News
Pregnant Women Should Delay Gallbladder Surgery, Study FindsGut Microbes May Help Drive Lupus, Study FindsMost Hip, Knee Replacements Last Decades, Study FindsAHA News: Living Near Convenience Stores Could Raise Risk of Artery-Clogging ConditionPossible Parkinson's 'Pandemic' Looms: Report'Apple-Shaped' Body? 'Pear-Shaped'? Your Genes May TellProtect Your Aging Eyes From Macular DegenerationKidney Failure Patients Face Higher Risk of Cancer DeathHow Inactivity and Junk Food Can Harm Your BrainTattooed and Need an MRI Scan? What You Need to KnowGot the Flu? You Probably Shouldn't Head to the ERStudy Reaffirms Safety of Hepatitis C Meds in Liver Cancer PatientsSmart Steps for Healthy FeetOpioids Overprescribed for Common Children's Fracture, Study SaysNew Hepatitis Meds Are Saving Lives: StudyGun Injuries Bring Especially Tough RecoveriesAspirin Can Help Prevent Colon Cancer, But Many at Risk Don't Take ItAre Scientists Closer to Growing Made-to-Order Kidneys?Worldwide, More Die After Surgery Than From HIV, Malaria: StudyBlood Thinning Drug May Be Safer Option Against Recurrent StrokeStudy Ties Cancer-Causing HPV to Heart Disease, TooDangerous Bacteria May Lurk in Hospital SinksAs U.S. Measles Outbreaks Spread, Why Does 'Anti-Vax' Movement Persist?Cablivi Approved for Rare Clotting DisorderNew Antibiotic Treats Pneumonia, Skin InfectionsOpioid OD Deaths Are Saving Lives Through TransplantationHealth Tip: Know Your Family's Medical HistoryAHA News: High Blood Pressure Top Risk Factor for Stroke in Young AdultsRethinking Blood Pressure ReadingsPsoriasis Meds Might Help Fight Heart Trouble, TooSurgery Restores Movement to Kids With Polio-Like IllnessYou've Fainted. How Long Do You Need to Stay in the ER?Could Germs in Your Gut Send You Into Depression?Health Tip: Prevent the Spread of Head LiceExercise Your Right to Fight DiseaseObesity-Linked Cancers On the Rise Among Young AmericansUnraveling the Mystery of HiccupsAHA: 7 Things That Can Affect the Heart -- And What to Do About ThemStatins Help the Heart, No Matter What Your AgeFirst Generic Version of Advair Diskus Approved for Asthma, COPDMore Smoking, Heart Woes Boost Native Americans' Stroke RiskNearly Half of American Adults Have Unhealthy Hearts: ReportHealth Tip: Avoid Winter Skin RashesHow to Prevent and Treat Eye AllergiesPolar Vortex Brings Frostbite Danger: Protect YourselfAHA: Could a Heart Attack or Stroke Lead to Early Menopause?Dirty Air Tied to Raised Risk of Strokes, Shorter LivesVaping Tied to Rise in Stroke, Heart Attack RiskPill Expands in Your Stomach to Spot and Track DiseaseFlu May Up the Odds of Stroke, Neck Artery Tears
Questions and AnswersLinks
Related Topics

Diabetes

Cablivi Approved for Rare Clotting Disorder

HealthDay News
by -- Scott Roberts
Updated: Feb 6th 2019

WEDNESDAY, Feb. 6, 2019 (HealthDay News) -- Cablivi (caplacizumab-yhdp) injection has been approved by the U.S. Food and Drug Administration to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and deadly disorder that causes blood clotting.

"Patients with aTTP endure hours of treatment with daily plasma exchange, which requires being attached to a machine that takes blood out of the body and mixes it with donated plasma and then returns it to the body. Even after days or weeks of this treatment, as well as taking drugs that suppress the immune system, many patients will have a recurrence of aTTP," said Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence.

People with aTTP develop blood clots in the small blood vessels throughout the body. The clots can cut off oxygen and blood supply to the major organs and cause strokes and heart attacks, the agency said Wednesday in a news release. Patients with cancer, HIV, pregnancy, lupus or infections are at greater risk of developing the disorder.

Cablivi was evaluated in clinical studies involving 145 people. Those treated with Cablivi had fewer instances of aTTP-related death, the FDA said.

Common side effects include headache and bleeding of the nose or gums.

Cablivi's prescribing information includes a warning about the risk of severe bleeding. Health care providers should monitor closely people who also take blood-thinning medications, the FDA said.

The drug is produced by Ablynx, based in Belgium.